Results 151 to 160 of about 5,710 (181)

Evolocumab in Hyperlipidemia

New England Journal of Medicine, 2014
Dirk J, Blom, Scott M, Wasserman, Evan A, Stein   +2 more
openaire   +4 more sources

Evolocumab

Practical Diabetes, 2017
Louise McKenna, Gerry McKay, Miles Fisher   +2 more
openaire   +2 more sources

Myocardial Infarction and Evolocumab

JAMA Cardiology, 2021
Harvey D, White, Philippe Gabriel, Steg, Gregory G, Schwartz   +2 more
openaire   +4 more sources

Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease

Circulation, 2022
J Antonio G Lopez, Marc S Sabatine, Stephen Wiviott   +2 more
exaly  

Evolocumab

Reactions Weekly, 2018
openaire   +2 more sources

Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials

European Heart Journal, 2022
Anton Camaj
exaly  

Evolocumab (Repatha)

Canadian Journal of Health Technologies
It is recommended that Repatha be reimbursed by public drug plans for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in adult patients with primary hyperlipidemia (atherosclerotic cardiovascular disease [ASCVD]) if certain conditions are met. Repatha should only be covered to treat patients with a recent acute coronary syndrome (
openaire   +2 more sources

Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study

Atherosclerosis, 2023
Christoph Ebenbichler, Anja Vogt, Eric Bruckert   +2 more
exaly  

Evolocumab in patients with homozygous familial hypercholesterolemia in India

Journal of Clinical Lipidology, 2021
Vimal Mehta, Frederick J Raal
exaly  

Evolocumab, a PCSK9 inhibitor, protects human endothelial cells against H2O2-induced oxidative stress

Archives of Physiology and Biochemistry, 2022
Leila Safaeian, Mina Mirian
exaly